Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
Following concerns about the safety and reactogenicity profile of diphtheria, tetanus and whole cell pertussis vaccines (DTwP), new and less reactogenic alternatives were developed over the last two decades. The new diphtheria, tetanus and acellular pertussis vaccines (DTaP) no longer consist of the whole bacterial cell but of either extracts or of a few highly purified components. While it soon became clear that DTaP vaccines are significantly less reactogenic than DTwP vaccines, their efficacy was disputed and remained unproven. First studies and epidemiological data from Japan suggested vaccine efficacy rates (VE) of about 80%; however, the first blinded clinical trial from Sweden documented a much lower VE. Worldwide, seven large DTaP efficacy trials have recently been completed. Our own efforts included a large safety trial with 22505 vaccinees and, nested in this setting, a prospective household contact study. Typical WHO-defined pertussis developed in 7 of 112 DTaP vaccinated children following household exposure as compared to 96 cases in 173 children not vaccinated against pertussis. Thus, vaccine efficacy was calculated to be 88.7% (95% CI 76.6 to 94.6). The median duration of spasmodic cough in the few children vaccinated with DTaP who did start coughing was 17 days as compared to 35 days in unvaccinated children. No waning of protection was observed. None of the confounding variables analyzed influenced study results in favour of DTaP. Following administration of more than 67000 DTaP doses, 153 serious adverse events were reported. Eight events were considered possibly related and five were considered related to the study vaccine. According to additional study results from the other trials it can be concluded that DTaP vaccines, like DTwP vaccines, are safe and effective. The choice between DTwP and DTaP should be based on acceptance of the reactogenicity profile, coverage rates achieved, costs and other factors in each individual country.
Weigl
J A
JA
Hospital-Department of General Paediatrics, Christian-Albrecht University, Kiel, Germany.
Bock
H L
HL
Clemens
R
R
Zepp
F
F
Habermehl
P
P
Beutel
K
K
Müschenborn
S
S
Sümenicht
G
G
Schuind
A
A
von König
C H
CH
Neiss
A
A
Laukamp
S
S
Kiederle
S
S
Schmitt
H J
HJ
D002986:Clinical Trials as Topic; D015331:Cohort Studies; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006801:Humans; D014917:Whooping Cough / Q000517:prevention & control / Q000635:transmission
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines